Apolipoprotein E increases cell association of amyloid-β 40 through heparan sulfate and LRP1 dependent pathways

References

• Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, et al. Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science 2010;330:1774
   PubMed Web of Science ®Google Scholar
• Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Science Transl Med 2011;3:89ra57
   PubMed Web of Science ®Google Scholar
• Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 2009;10:333–44
   PubMed Web of Science ®Google Scholar
• Tokuda T, Calero M, Matsubara E, Vidal R, Kumar A, Permanne B, Zlokovic B, et al. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer’s amyloid beta peptides. Biochem J 2000;348:359–65
   PubMed Web of Science ®Google Scholar
• Weisgraber KH, Rall SC, Mahley RW. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem 1981;256:9077–83
   PubMed Web of Science ®Google Scholar
• Zhong N, Weisgraber KH. Understanding the association of apolipoprotein E4 with Alzheimer disease: clues from its structure. J Biol Chem 2009;284:6027–31
   PubMedGoogle Scholar
• Fuentealba RA, Liu Q, Zhang J, Kanekiyo T, Hu X, Lee JM, LaDu MJ, et al. Low-density lipoprotein receptor-related protein 1 (LRP1) mediates neuronal Abeta42 uptake and lysosomal trafficking. PLoS One 2010;5:e11884
   PubMedGoogle Scholar
• Sandwall E, O’Callaghan P, Zhang X, Lindahl U, Lannfelt L, Li JP. Heparan sulfate mediates amyloid-beta internalization and cytotoxicity. Glycobiology 2010;20:533–41
   PubMedGoogle Scholar
• Kanekiyo T, Zhang J, Liu Q, Liu CC, Zhang L, Bu G. Heparan sulphate proteoglycan and the low-density lipoprotein receptor-related protein 1 constitute major pathways for neuronal amyloid-beta uptake. J Neurosci 2011;31:1644–51
   PubMedGoogle Scholar
• Giulian D, Haverkamp LJ, Yu J, Karshin W, Tom D, Li J, Kazanskaia A, et al. The HHQK domain of beta-amyloid provides a structural basis for the immunopathology of Alzheimer’s disease. J Biol Chem 1998;273:29719–26
   PubMed Web of Science ®Google Scholar
• Lindahl B, Westling C, Giménez-Gallego G, Lindahl U, Salmivirta M. Common binding sites for β-amyloid fibrils and fibroblast growth factor-2 in heparan sulfate from human cerebral cortex. J Biol Chem 1999;274:30631–5
   PubMed Web of Science ®Google Scholar
• Woods AG, Cribbs DH, Whittemore ER, Cotman CW. Heparan sulfate and chondroitin sulfate glycosaminoglycan attenuate β-amyloid(25-35) induced neurodegeneration in cultured hippocampal neurons. Brain Res 1995;697:53–62
   PubMedGoogle Scholar
• Timmer NM, Schirris TJJ, Bruinsma IB, Otte-Höller I, van Kuppevelt TH, de Waal RMW, Verbeek MM. Aggregation and cytotoxic properties towards cultured cerebrovascular cells of Dutch-mutated Aβ40 (DAβ1-40) are modulated by sulfate moieties of heparin. Neurosci Res 2009;66:380–9
   PubMedGoogle Scholar
• Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 2004;43:333–44
   PubMed Web of Science ®Google Scholar
• Bell RD, Deane R, Chow N, Long X, Sagare A, Singh I, Streb JW, et al. SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat Cell Biol 2009;11:143–53
   PubMed Web of Science ®Google Scholar
• Pflanzner T, Janko MC, Andre-Dohmen B, Reuss S, Weggen S, Roebroek AJ, Kuhlmann CR, et al. LRP1 mediates bidirectional transcytosis of amyloid-beta across the blood-brain barrier. Neurobiol Aging 2011;32:2323.e1–11
   Google Scholar
• Nazer B, Hong S, Selkoe DJ. LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-[beta] peptide in a blood-brain barrier in vitro model. Neurobiol Dis 2008;30:94–102
   PubMed Web of Science ®Google Scholar
• Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, et al. Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier. J Clin Invest 2000;106:1489–99
   PubMed Web of Science ®Google Scholar
• Cardin AD, Hirose N, Blankenship DT, Jackson RL, Harmony JA, Sparrow DA, Sparrow JT. Binding of a high reactive heparin to human apolipoprotein E: identification of two heparin-binding domains. Biochem Biophys Res Commun 1986;134:783–9
   PubMed Web of Science ®Google Scholar
• Yamauchi Y, Deguchi N, Takagi C, Tanaka M, Dhanasekaran P, Nakano M, Handa T, et al. Role of the N- and C-terminal domains in binding of apolipoprotein E isoforms to heparan sulfate and dermatan sulfate: a surface plasmon resonance study. Biochemistry (Mosc) 2008;47:6702–10
   Google Scholar
• Mahley RW, Ji Z-S. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res 1999;40:1–16
   PubMed Web of Science ®Google Scholar
• Wilsie LC, Orlando RA. The low density lipoprotein receptor-related protein complexes with cell surface heparan sulfate proteoglycans to regulate proteoglycan-mediated lipoprotein catabolism. J Biol Chem 2003;278:15758–64
   PubMedGoogle Scholar
• Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA 2000;97:2892–7
   PubMed Web of Science ®Google Scholar
• Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, et al. ApoE promotes the proteolytic degradation of Abeta. Neuron 2008;58:681–93
   PubMed Web of Science ®Google Scholar
• Bruinsma IB, Wilhelmus MMM, Kox M, Veerhuis R, de Waal RMW, Verbeek MM. Apolipoprotein E protects cultured pericytes and astrocytes from D-Abeta 1-40-mediated cell death. Brain Res 2010;1315:169–80
   PubMedGoogle Scholar
• Bruinsma I, te Riet L, Gevers T, ten Dam G, van Kuppevelt T, David G, Küsters B, et al. Sulfation of heparan sulfate associated with amyloid-β plaques in patients with Alzheimer’s disease. Acta Neuropathol (Berl) 2010;119:211–20
   PubMedGoogle Scholar
• Näslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA 2000;283:1571–7
   PubMed Web of Science ®Google Scholar
• Sehlin D, Hedlund M, Lord A, Englund H, Gellerfors P, Paulie S, Lannfelt L, et al. Heavy-chain complementarity-determining regions determine conformation selectivity of anti-Aβ antibodies. Neurodegener Dis 2011;8:117–23
   PubMed Web of Science ®Google Scholar
• Englund H, Sehlin D, Johansson A-S, Nilsson LNG, Gellerfors P, Paulie S, Lannfelt L, et al. Sensitive ELISA detection of amyloid-β protofibrils in biological samples. J Neurochem 2007;103:334–45
   PubMed Web of Science ®Google Scholar
• Staatz WD, Toyoda H, Kinoshita-Toyoda A, Chhor K, Selleck SB. Analysis of proteoglycans and glycosaminoglycans from Drosophila. Methods Mol Biol 2001;171:41–52
   PubMedGoogle Scholar
• Hook GE, Gilmore LB. Hydrolases of pulmonary lysosomes and lamellar bodies. J Biol Chem 1982;257:9211–20
   PubMedGoogle Scholar
• Kreuger J, Lindahl U, Jemth P. Nitrocellulose filter binding to assess binding of glycosaminoglycans to proteins. Meth Enzymol 2003;363:327–39
   PubMedGoogle Scholar
• Donahue J, Flaherty S, Johanson C, Duncan J, Silverberg G, Miller M, Tavares R, et al. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol (Berl) 2006;112:405–15
   PubMed Web of Science ®Google Scholar
• O’Callaghan P, Sandwall E, Li J-P, Yu H, Ravid R, Guan Z-Z, Van Kuppevelt TH, et al. Heparan sulfate accumulation with Aβ deposits in Alzheimer's disease and Tg2576 mice is contributed by glial cells. Brain Pathol 2008;18:548–61
   PubMedGoogle Scholar
• Yamada K, Hashimoto T, Yabuki C, Nagae Y, Tachikawa M, Strickland DK, Liu Q, et al. The low density lipoprotein receptor-related protein 1 mediates uptake of amyloid beta peptides in an in vitro model of the blood-brain barrier cells. J Biol Chem 2008;283:34554–62
   PubMedGoogle Scholar
• Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ. Sequence of deposition of heterogeneous amyloid β-peptides and ApoE in Down Syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis 1996;3:16–32
   PubMed Web of Science ®Google Scholar
• Gearing M, Schneider JA, Robbins RS, Hollister RD, Mori H, Games D, Hyman BT, et al. Regional variation in the distribution of apolipoprotein E and Abeta in Alzheimer’s disease. J Neuropathol Exp Neurol 1995;54:833–41
   PubMedGoogle Scholar
• Marques MA, Tolar M, Harmony JA, Crutcher KA. A thrombin cleavage fragment of apolipoprotein E exhibits isoform-specific neurotoxicity. Neuroreport 1996;7:2529–32
   PubMedGoogle Scholar
• Tolar M, Marques MA, Harmony JA, Crutcher KA. Neurotoxicity of the 22 kDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated. J Neurosci 1997;17:5678–86
   PubMedGoogle Scholar
• Li J, Kanekiyo T, Shinohara M, Zhang Y, LaDu MJ, Xu H, Bu G. Differential regulation of amyloid-β endocytic trafficking and lysosomal degradation by apolipoprotein E isoforms. J Biol Chem 2012;287:44593–601
   PubMed Web of Science ®Google Scholar
• Chen J, Li Q, Wang J. Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions. Proc Natl Acad Sci USA 2011;108:14813–18
   PubMed Web of Science ®Google Scholar
• Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, Schmechel D, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993;90:8098–102
   PubMed Web of Science ®Google Scholar
• Naslund J, Thyberg J, Tjernberg LO, Wernstedt C, Karlstrom AR, Bogdanovic N, Gandy SE, et al. Characterization of stable complexes involving apolipoprotein E and the amyloid beta peptide in Alzheimer’s disease brain. Neuron 1995;15:219–28
   PubMedGoogle Scholar
• Wolburg H, Noell S, Mack A, Wolburg-Buchholz K, Fallier-Becker P. Brain endothelial cells and the glio-vascular complex. Cell Tissue Res 2009;335:75–96
   PubMedGoogle Scholar
• Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008;57:178–201
   PubMed Web of Science ®Google Scholar
• Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, et al. apoE isoform specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest 2008;118:4002–13
   PubMed Web of Science ®Google Scholar
• Wu Z, Guo H, Chow N, Sallstrom J, Bell RD, Deane R, Brooks AI, et al. Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat Med 2005;11:959–65
   PubMed Web of Science ®Google Scholar
• Martel CL, Mackic JB, Matsubara E, Governale S, Miguel C, Miao W, McComb JG, et al. Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid β. J Neurochem 1997;69:1995–2004
   PubMed Web of Science ®Google Scholar
• Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A, Bu G, et al. ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions. Proc Natl Acad Sci USA 2013;110:E1807–16
   PubMed Web of Science ®Google Scholar
• Tai LM, Bilousova T, Jungbauer L, Roeske SK, Youmans KL, Yu C, Poon WW, et al. Levels of soluble apolipoprotein E/amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples. J Biol Chem 2013;288:5914–26
   PubMed Web of Science ®Google Scholar
• Iwatsubo T, Saido TC, Mann DM, Lee VM, Trojanowski JQ. Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. Am J Pathol 1996;149:1823–30
   PubMed Web of Science ®Google Scholar
• Gunn AP, Masters CL, Cherny RA. Pyroglutamate-Abeta: role in the natural history of Alzheimer’s disease. Int J Biochem Cell Biol 2010;42:1915–18
   PubMed Web of Science ®Google Scholar
• Englund H, Degerman Gunnarsson M, Brundin RM, Hedlund M, Kilander L, Lannfelt L, Pettersson FE. Oligomerization partially explains the lowering of Abeta42 in Alzheimer’s disease cerebrospinal fluid. Neurodegener Dis 2009;6:139–47
   PubMedGoogle Scholar
• Ji Z-S, Pitas RE, Mahley RW. Differential cellular accumulation/retention of apolipoprotein E mediated by cell surface heparan sulfate proteoglycans. J Biol Chem 1998;273:13452–60
   PubMed Web of Science ®Google Scholar
• Tamamizu-Kato S, Cohen JK, Drake CB, Kosaraju MG, Drury J, Narayanaswami V. Interaction with amyloid beta peptide compromises the lipid binding function of apolipoprotein E. Biochemistry (Mosc) 2008;47:5225–34
   Google Scholar
• Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest 2008;118:671–82
   PubMed Web of Science ®Google Scholar
• Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM. Deletion of Abca1 increases Aβ deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem 2005;280:43236–42
   PubMed Web of Science ®Google Scholar
• Koldamova R, Staufenbiel M, Lefterov I. Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J Biol Chem 2005;280:43224–35
   PubMedGoogle Scholar
• Murphy AJ, Akhtari M, Tolani S, Pagler T, Bijl N, Kuo C-L, Wang M, et al. ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. J Clin Invest 2011;121:4138–49
   PubMed Web of Science ®Google Scholar
• Hatters DM, Peters-Libeu CA, Weisgraber KH. Apolipoprotein E structure: insights into function. Trends Biochem Sci 2006;31:445–54
   PubMed Web of Science ®Google Scholar
• Gupta-Bansal R, Frederickson RC, Brunden KR. Proteoglycan-mediated inhibition of A beta proteolysis. A potential cause of senile plaque accumulation. J Biol Chem 1995;270:18666–71
   PubMed Web of Science ®Google Scholar